Here are five notes:
1. The product, NanoFUSE DBM, is a novel composite allograft.
2. It received expanded 510(k) marketing clearance from the FDA for use in spinal fusion surgery.
3. Under the license agreement, Nanotherapeutics will become a minority shareholder in Amend Surgical.
4. Amend Surgical is a medical technology company focused on enhancing the bone healing/regenerative capacity of bone grafts.
5. Financial terms of the transaction were not disclosed.
More articles on devices:
US spinal surgery market outlook to 2021 — 5 things to know
NuVasive, Smith & Nephew, Medtech & more: 21 key notes
Conmed completes $265M SurgiQuest acquisition: 4 takeaways
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
